Your browser doesn't support javascript.
loading
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Kreitman, Robert J; Moreau, Philippe; Ravandi, Farhad; Hutchings, Martin; Gazzah, Anas; Michallet, Anne-Sophie; Wainberg, Zev A; Stein, Alexander; Dietrich, Sascha; de Jonge, Maja J A; Willenbacher, Wolfgang; De Grève, Jacques; Arons, Evgeny; Ilankumaran, Palanichamy; Burgess, Paul; Gasal, Eduard; Subbiah, Vivek.
Afiliação
  • Kreitman RJ; Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD.
  • Moreau P; Department of Hematology, CHU de Nantes, Nantes, France.
  • Ravandi F; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hutchings M; Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
  • Gazzah A; Gustave Roussy Cancer Institute, Villejuif, France.
  • Michallet AS; Centre Léon Bérard, Lyon, France.
  • Wainberg ZA; Department of Medicine, UCLA, Los Angeles, CA.
  • Stein A; Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dietrich S; University of Heidelberg, Heidelberg, Germany.
  • de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Willenbacher W; Internal Medicine V: Hematology & Oncology, Medical University Innsbruck, Innsbruck, Austria.
  • De Grève J; Oncotyrol-Center for Personalized Cancer Medicine, Innsbruck, Austria.
  • Arons E; University Hospital Vrije Universiteit Brussel, Brussels, Belgium.
  • Ilankumaran P; Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD.
  • Burgess P; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Gasal E; Global Drug Development, Oncology Development Unit, Novartis Pharma AG, Basel, Switzerland.
  • Subbiah V; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Blood ; 141(9): 996-1006, 2023 03 02.
Article em En | MEDLINE | ID: mdl-36108341
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia de Células Pilosas / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia de Células Pilosas / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article